A Pioneering Step for Chinese Pharmaceutical Companies in MENA

We are excited to announce our partnership with Overseas Pharmaceuticals Ltd. (OPL), a leading innovator in controlled-release drug delivery systems (DDS). OPL is dedicated to developing next-generation medicines that enhance drug safety, efficacy and patient compliance. With both FDA and NMPA approvals on its flagship product, OPL has built a robust pipeline spanning multiple therapeutic areas, including 30+ IND-approved products, positioning it for a projected $12.3 billion peak sales in the US and Chinese markets. Now, as part of its global expansion strategy, OPL is entering the MENA region to bring its cutting-edge therapies to new markets.

This collaboration also represents a pioneering step for Chinese pharmaceutical companies in the MENA region, a market with vast potential yet few CN players. By working together, OPL and IPDL aim to establish a successful pathway for China's pharmaceutical innovations to access and thrive in MENA, paving the way for future entrants. This partnership is driven by a shared commitment to bringing innovative healthcare solutions to MENA, and we look forward to driving successful market entry and impactful collaborations in the region.